NEW YORK – The GenomeWeb Index rose nearly 13 percent in July, as investors once again sought to reward companies that seemed to be making significant developments with their SARS-CoV-2 diagnostics.
The index outperformed the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index, which rose 2 percent, 7 percent, and nearly 2 percent, respectively. Individual stock performances in the GenomeWeb Index were overwhelmingly positive in July, as 28 of the 32 stocks saw gains and only four saw losses.